Dr. Rupali K. Nabar, MD

Dr. Nabar practices at UCI Health - Orange in Orange, California, part of UC Irvine.

Dr. Nabar's NPI, 1902062839, was assigned on July 30, 2008. Dr. Nabar graduated from Ohio State College of Medicine in 2005. Dr. Nabar holds California license A98523.

Dr. Nabar's primary practice is UCI Health - Orange, at 101 City Drive South, Orange, CA 92868 in Orange County. The practice phone is (714) 456-7890.

Dr. Nabar's primary practice is UCI Health - Orange in Orange, California, part of UC Irvine. Dr. Nabar is also affiliated with Hoag Hospital Newport Beach. The medical group on file is UCI Health Physicians. Dmand AI also links Dr. Nabar to 1 more physician office, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Nabar practices, 3 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Nabar's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Nabar is licensed in California.

Dmand AI lists acute kidney failure, chronic anemia, chronic embolism thrombosis, deep vein thrombosis (DVT), immune deficiency disease, neutropenia, osteoporosis and purpura and thrombocytopenia among the conditions Dr. Nabar treats.

CMS data shows 774 Medicare services from Dr. Nabar across 4 procedure codes in 2024, for 276 Medicare patients. Medicare paid $114,428 for them.

CMS counts 276 Medicare patients who saw Dr. Nabar in 2024. The largest group is 65 to 74, with 130 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 29% are also on Medicaid. Their average risk score is 2.25, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Nabar's median patient age at 67, with 49% women.

In 2024, Dr. Nabar wrote 719 Medicare Part D claims for 122 patients. 83% of them were for generic drugs. CMS names the drug for 464 of them, across 16 drugs with 11 or more claims each, at $561,202 in total drug cost. In 2023, CMS named 384 claims across 15 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Nabar for performance year 2024, reported through an alternative payment model (APM). Dr. Nabar accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Nabar as offering telehealth.

Dmand AI links 4 papers to Dr. Nabar, published from 2019 to 2024. 2023 was the busiest year, with 2. The most frequent topics are Carcinoma, Squamous Cell, Chemoradiotherapy and Cisplatin. Dr. Nabar's most frequent co-authors are William Armstrong, MD, Yarah Mahmoud Haidar, MD and Tjoson Tjoa, MD.

Dmand AI links Dr. Nabar to 1 clinical trial. 1 is still active or recruiting. Conditions studied include Nasopharyngeal Carcinoma and Nasopharyngeal Diseases.

CMS Open Payments shows 5 general payments to Dr. Nabar from 5 drug and device companies from 2016 to 2023. Food and beverage make up the largest share, 100% of the total. Coherus Biosciences Inc. paid the most, $121.

Dmand AI lists 3 awards for Dr. Nabar, most recently National Dean's List in 1998.

Dr. Nabar graduated from Ohio State College of Medicine in 2005.

Dr. Nabar is in network with 13 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 9. Check the plan with the practice before a visit.